551.57

0.18% -1.50

Idexx Laboratories Inc (IDXX)

Overview News Price History Option Chain Financials Why IDXX Down? Discussions Forecast Stock Split

Idexx Laboratories Inc stock is traded at $551.57, with a volume of 7,059. It is down -0.18% in the last 24 hours and down -4.54% over the past month. Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.

Previous Close:

$553.07

Open:

$551.46

24h Volume:

7,059

Relative Volume:

0.01

Market Cap:

$43.37B

Revenue:

$4.45B

Net Income/Loss:

$1.10B

P/E Ratio:

40.58

EPS:

13.591

Net Cash Flow:

$1.06B

1W Performance:

+4.41%

1M Performance:

-4.54%

6M Performance:

-23.94%

1Y Performance:

+9.36%

1-Day Range:

$549.75

$555.51

1-Week Range:

$531.70

$561.28

52-Week Range:

$496.61

$769.98

Idexx Laboratories Inc Stock (IDXX) Company Profile

Name

Idexx Laboratories Inc

Sector

Healthcare (1107)

Industry

Diagnostics & Research (52)

Phone

(207) 556-0300

Address

ONE IDEXX DRIVE, WESTBROOK, ME

Employee

11,000

Twitter

@idexx

Next Earnings Date

2026-05-05

Latest SEC Filings

IDXX's Discussions on Twitter

Compare IDXX vs TMO, DHR, WAT, A

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IDXX Idexx Laboratories Inc	549.75	43.63B	4.45B	1.10B	1.06B	13.59
TMO Thermo Fisher Scientific Inc	448.93	167.00B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	173.76	122.68B	24.78B	3.68B	5.29B	5.1743
WAT Waters Corp	341.44	33.48B	3.77B	449.25M	240.68M	7.8556
A Agilent Technologies Inc	114.54	32.44B	7.07B	1.29B	993.00M	4.5355

Idexx Laboratories Inc Stock (IDXX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-15-26	Initiated	Citigroup	Neutral
Dec-09-25	Initiated	Barclays	Overweight
Oct-31-25	Upgrade	Stifel	Hold → Buy
Oct-01-25	Initiated	UBS	Neutral
Aug-05-25	Reiterated	BTIG Research	Buy
Jul-01-25	Initiated	Jefferies	Buy
Dec-02-24	Initiated	Leerink Partners	Outperform
Jul-25-24	Initiated	BTIG Research	Buy
Jan-30-24	Downgrade	Piper Sandler	Overweight → Neutral
Dec-07-23	Initiated	Exane BNP Paribas	Outperform
Dec-04-23	Upgrade	Cleveland Research	Neutral → Buy
Aug-02-23	Downgrade	Atlantic Equities	Overweight → Neutral
Jul-25-22	Downgrade	Stifel	Buy → Hold
Jul-21-22	Upgrade	Goldman	Neutral → Buy
Jul-12-22	Initiated	Piper Sandler	Overweight
May-05-22	Downgrade	BofA Securities	Buy → Neutral
Feb-08-22	Initiated	Atlantic Equities	Overweight
Nov-18-21	Initiated	Morgan Stanley	Overweight
Aug-05-21	Resumed	Credit Suisse	Outperform
Jul-12-21	Downgrade	Guggenheim	Buy → Neutral
Feb-17-21	Initiated	Barclays	Overweight
Sep-09-19	Initiated	Goldman	Neutral
May-23-19	Initiated	Guggenheim	Buy
Nov-02-18	Reiterated	BofA/Merrill	Buy
May-07-18	Reiterated	Stifel	Buy
Jan-16-18	Initiated	Piper Jaffray	Overweight
Aug-23-17	Upgrade	BofA/Merrill	Neutral → Buy
Jul-28-17	Upgrade	CL King	Neutral → Buy
Feb-03-17	Downgrade	Feltl & Co.	Hold → Sell
Sep-29-16	Resumed	BofA/Merrill	Neutral
Aug-16-16	Reiterated	Stifel	Buy
Aug-03-16	Upgrade	Northcoast	Sell → Neutral
Jul-20-16	Reiterated	Canaccord Genuity	Buy
Apr-19-16	Reiterated	Canaccord Genuity	Buy
Apr-01-16	Initiated	CL King	Neutral
Mar-21-16	Reiterated	Stifel	Buy
Feb-04-16	Initiated	Credit Suisse	Outperform
Oct-29-15	Reiterated	Stifel	Buy
Aug-28-15	Downgrade	Raymond James	Outperform → Mkt Perform
Aug-13-15	Reiterated	Stifel	Buy
Jul-23-15	Reiterated	Canaccord Genuity	Buy

View All

Idexx Laboratories Inc Stock (IDXX) Latest News

05:46 AM

IDEXX Laboratories stock (US45168D1046): institutional selldown and animal health growth story - AD HOC NEWS

05:46 AM

May 20, 2026

Insider sale notice: IDEXX Labs (NASDAQ: IDXX) files Form 144 - Stock Titan

May 20, 2026

IDEXX Laboratories Inc. stock outperforms competitors on strong trading day - MarketWatch

May 20, 2026

Should IDEXX’s (IDXX) SDMA-Enhanced Catalyst Panels Prompt Action From Long-Term Diagnostics Investors? - Yahoo Finance

May 20, 2026

IDEXX announces UK availability of cancer Dx panel for early detection of canine lymphoma - MSN

May 20, 2026

May 19, 2026

IDEXX Laboratories stock (US45168D1046): Q1 2026 earnings beat, guidance hike and new kidney test in - AD HOC NEWS

May 19, 2026

IDEXX Laboratories stock (US45168D1046): Q1 2026 earnings beat and updated guidance keep veterinary - AD HOC NEWS

May 19, 2026

IDEXX SDMA Now Integrated into the Most Common Catalyst Chemistry Profiles - Business Wire

May 19, 2026

IDEXX SDMA Rollout Ties Earlier Kidney Detection To Valuation Debate - Sahm

May 19, 2026

May 18, 2026